3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Oxaliplatin
300
Fluorouracil
273
Bevacizumab
238
Gemcitabine
236
Leucovorin
213
Capecitabine
207
pembrolizumab
202
Irinotecan
159
Nivolumab
158
Cisplatin
150
Specimen Handling
144
Magnetic Resonance Spectroscopy
130
130-nm albumin-bound paclitaxel
119
Paclitaxel
109
durvalumab
107
Cetuximab
104
Radiotherapy
99
atezolizumab
94
Drug Therapy
94
Biopsy
93
tislelizumab
81
Albumin-Bound Paclitaxel
81
Taxes
74
Folfox protocol
68
lenvatinib
67
Carboplatin
66
regorafenib
60
Blood Specimen Collection
60
sintilimab
54
Ipilimumab
53
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
gadoterate meglumine
×
Gastrointestinal
×
1 year
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled